BioNTech
BNTX
147 hedge funds and large institutions have $1.66B invested in BioNTech in 2020 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 49 increasing their positions, 26 reducing their positions, and 21 closing their positions.
181% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 21
88% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 26
35% more funds holding
Funds holding: 109 → 147 (+38)
1.45% less ownership
Funds ownership: 11.65% → 10.2% (-1.4%)
6% less capital invested
Capital invested by funds: $1.78B → $1.66B (-$115M)
47% less call options, than puts
Call options by funds: $99.7M | Put options by funds: $190M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$97.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$64.6M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$46.1M |
| 4 |
Temasek Holdings
Singapore
|
+$38.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$35.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$410M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$132M |
| 3 |
HM
HealthCor Management
New York
|
-$33.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$25.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$19.7M |
BNTX Hedge Fund Activity: Q3 2020 in Review
147 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q3 2020, worth a combined $1.66B — down 6.5% from $1.78B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BNTX positions and 21 closed out — a net gain of 38 holders — while 49 added to existing stakes and 26 trimmed.
The largest buyer was Primecap Management, adding an estimated $97.1M. The largest seller was Fidelity Investments, cutting an estimated $410M.
- 147 institutional investors held BioNTech (BNTX) as of Q3 2020, up from 109 in Q2 2020.
- Funds reported $1.66B of BioNTech stock for Q3 2020, down 6.5% quarter-over-quarter.
- 59 funds opened new BioNTech positions in Q3 2020 and 21 closed out, a net change of +38 holders.
- The largest BioNTech buyer in Q3 2020 was Primecap Management, an estimated $97.1M added.
- The largest BioNTech seller in Q3 2020 was Fidelity Investments, an estimated $410M sold.
Based on aggregated 13F filings for Q3 2020.